









市场行情
/
股票
/
nasdaq-adap
/

Adaptimmune Therapeutics PLC

ADAP

0.055USD

0.000

收盘 12/19, 16:00（美东）报价延迟15分钟

87.31M总市值

亏损市盈率 TTM



Adaptimmune Therapeutics PLC

0.055

0.000

概览公司财务分析

概览

公司

财务

分析

关于 Adaptimmune Therapeutics PLC 公司

Adaptimmune Therapeutics PLC is focused on pre-clinical programs, including PRAME and CD70-directed T-cell therapies, and its allogeneic pipeline. PRAME is highly expressed across a range of solid tumors, including ovarian, endometrial, lung and breast cancers. The CD70 program targets the CD70 antigen, which is expressed across a range of hematological malignancies (acute myeloid leukemia and lymphoma) and solid tumors (renal cell carcinoma). It is using TRuC technology to develop a T-cell therapy (ADP-520) against CD70, with membrane bound IL-15 to enhance persistence. ADP-520 is in pre-clinical testing. TRuC technology combines the targeting of CAR-T cells with T-cell TCR signaling.

Adaptimmune Therapeutics PLC简介



公司代码ADAP

公司名称Adaptimmune Therapeutics PLC

上市日期May 06, 2015

CEORawcliffe (Adrian George)

员工数量506

证券类型Depository Receipt

年结日May 06

公司地址60 Jubilee Avenue

城市ABINGDON

上市交易所NASDAQ Capital Market Consolidated

国家United Kingdom

邮编OX14 4RX

电话441235430000

网址https://www.adaptimmune.com/

公司代码ADAP

上市日期May 06, 2015

CEORawcliffe (Adrian George)

Adaptimmune Therapeutics PLC公司高管



名称

名称/职务

职务

持股

持股变动

Dr. Garry E. Menzel, Ph.D.

Non-Executive Independent Director

611.22K

+191.15%

Mr. Lawrence M. (Larry) Alleva, CPA

Non-Executive Independent Director

23.89K

Mr. Christopher Hill

Chief Financial Officer

Mr. Adrian Rawcliffe

Chief Executive Officer, Director

Mr. William C. (Bill) Bertrand, Jr., Esq.

Chief Operating Officer

Mr. John P. Furey

Non-Executive Independent Director

Dr. Ali Behbahani, M.D.

Non-Executive Independent Director

Mr. David M. (Dave) Mott

Non-Executive Independent Chairman of the Board

Dr. Andrew Allen, M.D., Ph.D.

Non-Executive Independent Director

Dr. Kristen M. Hege, M.D.

Non-Executive Independent Director

名称

名称/职务

职务

持股

持股变动

Dr. Garry E. Menzel, Ph.D.

Non-Executive Independent Director

611.22K

+191.15%

Mr. Lawrence M. (Larry) Alleva, CPA

Non-Executive Independent Director

23.89K

Mr. Christopher Hill

Chief Financial Officer

Mr. Adrian Rawcliffe

Chief Executive Officer, Director

Mr. William C. (Bill) Bertrand, Jr., Esq.

Chief Operating Officer

Mr. John P. Furey

Non-Executive Independent Director

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 11月16日周日

持股股东

股东类型

持股股东

占比

Long Focus Capital Management LLC

7.01%

UBS Financial Services, Inc.

2.47%

Renaissance Technologies LLC

1.53%

Morgan Stanley & Co. LLC

1.38%

Jane Street Capital, L.L.C.

1.06%

其他

86.56%

持股股东

占比

Long Focus Capital Management LLC

7.01%

UBS Financial Services, Inc.

2.47%

Renaissance Technologies LLC

1.53%

Morgan Stanley & Co. LLC

1.38%

Jane Street Capital, L.L.C.

1.06%

其他

86.56%

股东类型

持股股东

占比

Hedge Fund

8.54%

Investment Advisor

3.42%

Research Firm

2.99%

Investment Advisor/Hedge Fund

0.84%

Individual Investor

0.63%

Pension Fund

0.07%

Bank and Trust

0.05%

Venture Capital

0.04%

其他

83.43%

机构持股



更新时间: 12月8日周一

报告期

机构数

持股数

持股占比

持股变动

2025Q4

165

42.25M

57.79%

-8.12K

2025Q3

183

42.26M

58.51%

-57.25M

2025Q2

189

116.07M

65.05%

-1.37M

2025Q1

186

117.46M

62.78%

-44.42M

2024Q4

186

127.90M

58.86%

-11.67M

2024Q3

189

154.60M

64.35%

-2.20M

2024Q2

192

156.54M

67.34%

-7.97M

2024Q1

203

164.83M

67.18%

-6.80M

2023Q4

199

145.59M

71.95%

-5.54M

2023Q3

217

150.77M

70.44%

+3.59M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Long Focus Capital Management LLC

23.76M

8.96%

Jun 30, 2025

Renaissance Technologies LLC

1.88M

0.71%

+69.00K

+3.80%

Jun 30, 2025

Morgan Stanley & Co. LLC

4.22M

1.59%

+1.59M

+60.49%

Jun 30, 2025

Acadian Asset Management LLC

1.96M

0.74%

-254.07K

-11.45%

Jun 30, 2025

BofA Global Research (US)

1.14M

0.43%

-5.30K

-0.46%

Jun 30, 2025

Alpha Architect, LLC

800.00K

0.3%

+800.00K

Jun 30, 2025

Menzel (Garry E)

611.22K

0.23%

+401.29K

+191.15%

Apr 11, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

ActivePassive International Equity ETF

Fidelity Enhanced Small Cap ETF

SPDR S&P International Small Cap ETF

Invesco NASDAQ Future Gen 200 ETF

SPDR Portfolio Developed World ex-US ETF

ActivePassive International Equity ETF

占比0%

Fidelity Enhanced Small Cap ETF

占比0%

SPDR S&P International Small Cap ETF

占比0%

Invesco NASDAQ Future Gen 200 ETF

占比0%

SPDR Portfolio Developed World ex-US ETF

占比0%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

Adaptimmune Therapeutics PLC的前五大股东是谁？



Adaptimmune Therapeutics PLC 的前五大股东如下：
Long Focus Capital Management LLC持有股份：23.76M，占总股份比例：8.96%。
Renaissance Technologies LLC持有股份：1.88M，占总股份比例：0.71%。
Morgan Stanley & Co. LLC持有股份：4.22M，占总股份比例：1.59%。
Acadian Asset Management LLC持有股份：1.96M，占总股份比例：0.74%。
BofA Global Research (US)持有股份：1.14M，占总股份比例：0.43%。